Combination of Rituximab, Bendamustine, and Cytarabine for Patients With Mantle-Cell Non-Hodgkin Lymphoma Ineligible for Intensive Regimens or Autologous Transplantation | Zendy

Carlo Visco | Zendy; Silvia Finotto | Zendy; Renato Zambello | Zendy; Rossella Paolini | Zendy; Andrea Menin | Zendy; Roberta Zanotti | Zendy; Francesco Zaja | Zendy; Gianpietro Semenzato | Zendy; Giovanni Pizzolo | Zendy; Emanuele S.G. dʼAmore | Zendy; Francesco Rodeghiero | Zendy

Open Access

Combination of Rituximab, Bendamustine, and Cytarabine for Patients With Mantle-Cell Non-Hodgkin Lymphoma Ineligible for Intensive Regimens or Autologous Transplantation

Author(s) -

Carlo Visco,

Silvia Finotto,

Renato Zambello,

Rossella Paolini,

Andrea Menin,

Roberta Zanotti,

Francesco Zaja,

Gianpietro Semenzato,

Giovanni Pizzolo,

Emanuele S.G. dʼAmore,

Francesco Rodeghiero

Publication year - 2013

Publication title -

journal of clinical oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 10.482

H-Index - 548

eISSN - 1527-7755

pISSN - 0732-183X

DOI - 10.1200/jco.2012.45.9842

Subject(s) - medicine , cytarabine , bendamustine , mantle cell lymphoma , neutropenia , gastroenterology , rituximab , febrile neutropenia , surgery , transplantation , chemotherapy , lymphoma

The combination of bendamustine (B) and rituximab (R) is efficacious, with favorable toxicity in mantle-cell lymphoma (MCL). In this phase II study, we combined cytarabine with R and B (R-BAC) in patients with MCL age ≥ 65 years who were previously untreated or relapsed or refractory (R/R) after one prior immunochemotherapy treatment.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research